Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401)
收藏DataCite Commons2026-02-05 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002055/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study is designed as a Phase III, multicenter trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard Rituxan plus BEAM transplant regimen versus a regimen adding Bexxar to BEAM.
提供机构：
Vivli
创建时间：
2018-10-27
